These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Correction of fatal genetic diseases using bone marrow transplantation. 1]. Zintl F; Hermann J; Fuchs D; Prager J; Müller A; Reiners B; Füller J Kinderarztl Prax; 1991; 59(1-2):6-9. PubMed ID: 2056664 [TBL] [Abstract][Full Text] [Related]
29. Patients with early relapse of primary hemophagocytic syndromes or with persistent CNS involvement may benefit from immediate hematopoietic stem cell transplantation. Sparber-Sauer M; Hönig M; Schulz AS; zur Stadt U; Schütz C; Debatin KM; Friedrich W Bone Marrow Transplant; 2009 Sep; 44(6):333-8. PubMed ID: 19252534 [TBL] [Abstract][Full Text] [Related]
30. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. Handgretinger R; Kurtzberg J; Egeler RM Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316 [TBL] [Abstract][Full Text] [Related]
31. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Boelens JJ; Prasad VK; Tolar J; Wynn RF; Peters C Pediatr Clin North Am; 2010 Feb; 57(1):123-45. PubMed ID: 20307715 [TBL] [Abstract][Full Text] [Related]
32. Risk assessment in haematopoietic stem cell transplantation: stem cell source. Urbano-Ispizua A Best Pract Res Clin Haematol; 2007 Jun; 20(2):265-80. PubMed ID: 17448961 [TBL] [Abstract][Full Text] [Related]
33. [Therapy of hematologic disorders with stem cell transplantation]. Hirai H Nihon Naika Gakkai Zasshi; 2002 Mar; 91 Suppl():141-6. PubMed ID: 11989254 [No Abstract] [Full Text] [Related]
34. Unrelated bone marrow transplantation using a reduced intensity-conditioning regimen in leukocyte adhesion deficiency. Takahashi D; Nagatoshi Y; Saito Y; Inagaki J; Nagayama J; Shinkoda Y; Fujita K; Okamura J Bone Marrow Transplant; 2006 Apr; 37(8):807-8. PubMed ID: 16532019 [No Abstract] [Full Text] [Related]
35. Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Aschan J Br Med Bull; 2006; 77-78():23-36. PubMed ID: 16968691 [TBL] [Abstract][Full Text] [Related]
36. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
37. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813 [TBL] [Abstract][Full Text] [Related]
38. Chronic kidney dysfunction in patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Abboud I; Porcher R; Robin M; de Latour RP; Glotz D; Socié G; Peraldi MN Biol Blood Marrow Transplant; 2009 Oct; 15(10):1251-7. PubMed ID: 19747632 [TBL] [Abstract][Full Text] [Related]